Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Stress and the risk of multiple sclerosis.
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Ono to enter license agreements with Merck KGaA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
[Infections and fingolimod].
Shorter washout reduces MS relapse switching off natalizumab
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
A practical review of the neuropathology and neuroimaging of multiple sclerosis.

Pages